Table 1.
Sample | No. | Ct value (ORF1 RNA) | Group | LFA (P/N) | Dual-mode SERS-LFA | ||
---|---|---|---|---|---|---|---|
Ratio (TL1/CL) | P/N | ||||||
SARS-CoV-2 Positive |
P1 | 18.87 | < 20 | P | 1.601 | P | |
P2 | 22.78 | 20–25 | P | 0.215 | P | ||
P3 | 22.9 | P | 0.285 | P | |||
P4 | 23.47 | P | 0.54 | P | |||
P5 | 23.9 | N | 0.096 | P | |||
P6 | 24.59 | P | 0.209 | P | |||
P7 | 24.68 | P | 1.138 | P | |||
P8 | 24.95 | P | 0.107 | P | |||
P9 | 25.12 | 25–30 | P | 0.113 | P | ||
P10 | 25.83 | P | 0.133 | P | |||
P11 | 26.57 | P | 0.236 | P | |||
P12 | 26.65 | P | 0.123 | P | |||
P13 | 26.87 | N | 0.064 | P | |||
P14 | 27.34 | P | 0.072 | P | |||
P15 | 29.52 | N | 0.067 | P | |||
P16 | 29.69 | P | 0.292 | P | |||
P17 | 29.7 | N | 0.012 | N | |||
P18 | 30.07 | > 30 | P | 0.077 | P | ||
P19 | 30.45 | N | 0.142 | P | |||
P20 | 30.77 | N | 0.029 | N | |||
P21 | 31.25 | N | 0.042 | N | |||
P22 | 32.38 | N | 0.022 | N | |||
P23 | 32.83 | N | 0.108 | P | |||
P24 | 33.09 | N | 0.075 | P | |||
P25 | 33.88 | N | 0.018 | N | |||
P26 | 33.96 | N | 0.027 | N | |||
P27 | 34.85 | N | 0.080 | P | |||
P28 | 35.92 | N | 0.145 | P |
Sample | No. | Ct value ( M RNA) | Group | LFA (P/N) | Dual-mode SERS-LFA | ||
---|---|---|---|---|---|---|---|
Ratio (TL2/CL) | P/N | ||||||
Influenza A virus Positive |
P1 | 25 | 25–30 | P | 0.073 | P | |
P2 | 25.67 | P | 0.082 | P | |||
P3 | 25.67 | P | 0.335 | P | |||
P4 | 27.67 | N | 0.230 | P | |||
P5 | 32.67 | > 30 | P | 0.099 | P | ||
P6 | 33.67 | N | 0.082 | P |
Sample | No. | Ct value | Group | LFA (P/N) | Dual-mode SERS-LFA | ||
---|---|---|---|---|---|---|---|
Ratio (TL1/CL) | Ratio (TL2/CL) | P/N | |||||
Negative | N1 | N/A | Negative | N | 0.018 | 0.016 | N |
N2 | N/A | N | 0.029 | 0.027 | N | ||
N3 | N/A | N | 0.027 | 0.012 | N | ||
N4 | N/A | N | 0.022 | 0.017 | N | ||
N5 | N/A | N | 0.011 | 0.027 | N |